Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407409 | 0.98 | TLR8 (0.40) | TLR8TLR7TLR9MPOCHRNB2 | |
| SCHEMBL12069915 | 0.88 | HTR4 (0.39) | TLR8TLR7TLR9HTR4 | |
| SCHEMBL12940206 | 0.79 | ALDH1A1 (0.34) | HTR4 | |
| SCHEMBL12255455 | 0.77 | MPO (0.43) | TLR8TLR7TLR9MPO | |
| SCHEMBL16400128 | 0.76 | MPO (0.40) | TLR8TLR7TLR9MPO | |
| SCHEMBL2279604 | 0.76 | MPO (0.40) | TLR8TLR7TLR9MPO | |
| SCHEMBL15490000 | 0.75 | CYP2C19 (0.38) | HTR4 | |
| SCHEMBL15490002 | 0.75 | CYP2C19 (0.41) | — | |
| SCHEMBL12255457 | 0.75 | TLR9 (0.36) | TLR8TLR7TLR9MPOHTR4 | |
| SCHEMBL17481119 | 0.74 | CYP2C19 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | TLR8 4498/4885TLR7 4494/4885TLR9 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.